Bridgebio Pharma Inc
(BBIO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 681,227 | 392,588 | 414,619 | 393,949 | 356,082 |
| Marketable Securities | N/A | 58,949 | 95,233 | 442,891 | 251,011 |
| Receivables | 4,722 | 1,751 | 17,079 | 19,749 | N/A |
| TOTAL | $720,692 | $477,593 | $548,853 | $888,858 | $642,824 |
| Non-Current Assets | |||||
| PPE Net | 7,011 | 11,816 | 14,569 | 30,066 | 20,325 |
| Investments And Advances | 143,747 | 0 | 0 | 0 | 0 |
| Intangibles | 23,926 | 26,319 | 28,712 | 44,934 | 0 |
| Other Non-Current Assets | 23,962 | 30,652 | 30,902 | 48,934 | 40,439 |
| TOTAL | $198,646 | $68,787 | $74,183 | $123,934 | $60,764 |
| Total Assets | $919,338 | $546,380 | $623,036 | $1,012,792 | $703,588 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | N/A | N/A | 1,458 |
| Accounts payable and accrued liabilities | 9,618 | 10,655 | 11,558 | 11,884 | 8,945 |
| Accrued Expenses | 125,672 | 122,965 | 98,039 | 87,965 | 62,551 |
| Other current liabilities | N/A | N/A | N/A | N/A | 5,550 |
| TOTAL | $154,400 | $143,844 | $121,428 | $135,069 | $95,648 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,721,382 | 1,726,729 | 1,707,615 | 1,703,805 | 475,857 |
| Deferred Revenues | 14,604 | 6,096 | 8,156 | N/A | N/A |
| Other Non-Current Liabilities | 491,800 | 25,142 | 40,797 | 64,835 | 82,591 |
| TOTAL | $2,222,692 | $1,745,549 | $1,744,943 | $1,744,725 | $501,684 |
| Total Liabilities | $2,377,092 | $1,889,393 | $1,866,371 | $1,879,794 | $597,332 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 190,189 | 175,832 | 151,373 | 147,608 | 148,956 |
| Common Shares | 196 | 181 | 157 | 154 | 125 |
| Retained earnings | -3,096,263 | -2,560,501 | -1,918,149 | -1,436,966 | -888,755 |
| Other shareholders' equity | 10,158 | 11,275 | 10,954 | 3,280 | 48,542 |
| TOTAL | $-1,457,754 | $-1,343,013 | $-1,243,335 | $-867,002 | $106,256 |
| Total Liabilities And Equity | $919,338 | $546,380 | $623,036 | $1,012,792 | $703,588 |